LKT Labs

Biochemicals for Life Science Research

Lumiracoxib

Product ID L8248
Cas No. 220991-20-8
Purity ≥98%
Product Unit SizeCostQuantityStock
25 mg $61.50 In stock
100 mg $166.10 In stock
250 mg $319.50 In stock
1 g $971.10 In stock
Bulk Quote

Quicklinks

Description

Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that acts as an inhibitor of COX enzymes with specificity for COX-2. Like other NSAIDs, lumiracoxib exhibits anti-inflammatory, analgesic, antipyretic, and antinociceptive activities. In animal models of metabolic syndrome, lumiracoxib reverses vascular remodeling and inflammation. In animal models with experimental autoimmune encephalitis (EAE, a translational model of multiple sclerosis), lumiracoxib inhibits lymphocyte responses and decreases disease severity; in similar in vitro models, lumiracoxib inhibits T cell proliferation and modulates expression of T-bet, IL-10, and IFN-γ. This compound may also inhibit thromboxane receptors. Additionally, lumiracoxib exhibits some anticancer potential, inducing G0/G1 cell cycle arrest and apoptosis and inhibiting proliferation in non-small cell lung cancer (NSCLC) cell lines.

Product Info

Cas No.

220991-20-8
Purity

≥98%
Formula

C15H13ClFNO2
Formula Wt.

293.72
Chemical Name

2-[(2-Chloro-6-fluorophenyl)amino]-5-methylbenzeneacetic acid
IUPAC Name

2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid
Melting Point

158-159°C
Appearance

Pale Yellow Crystal

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

L8248 MSDS PDF
Info Sheet

L8248 Info Sheet PDF

References

Windsor MA, Valk PL, Xu S, et al. Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5860-4. PMID: 24060487.

Renna NF, Diez ER, Lembo C, et al. Role of Cox-2 in vascular inflammation: an experimental model of metabolic syndrome. Mediators Inflamm. 2013;2013:513251. PMID: 23476105.

Hao JQ, Li Q, Xu SP, et al. Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro. Chin Med J (Engl). 2008 Apr 5;121(7):602-7. PMID: 18466679.

Selg E, Buccellati C, Andersson M, et al. Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol. 2007 Dec;152(8):1185-95. Erratum in: Br J Pharmacol. 2008 Apr;153(8):1763. Ambrosio, E [corrected to Ambrosio, M]. PMID: 17965743.

Ni J, Shu YY, Zhu YN, et al. COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol. 2007 May;186(1-2):94-103. PMID: 17442406.

Esser R, Berry C, Du Z, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50. PMID: 15655513.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.